• Above all, we make a difference.
  • Survivorship Topics References


    1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta, GA: American Cancer Society, 2016.
    2. National Cancer Institute. Division of Cancer Control & Population Sciences, Office of Cancer Survivorship. Definitions. http://cancercontrol.cancer.gov/ocs/statistics/definitions.html, 2014.
    3. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.3.2018. http://www.nccn.org, 2018.
    4. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 31(7):961-5, 2013.
    5. American Society of Clinical Oncology (ASCO). Follow-up care for breast cancer. http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/follow-care-breast-cancer, 2015.
    6. American Congress of Obstetricians and Gynecologists. Well-woman visit. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Well-Woman-Visit, 2016.
    7. American Cancer Society. The American Cancer Society guidelines for the prevention and early detection of cervical cancer. https://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/cervical-cancer-screening-guidelines.html, 2016.
    8. Centers for Disease Control and Prevention. What cancer patients, survivors, and caregivers should know about the flu. https://www.cdc.gov/cancer/flu/basic-info.htm, 2018.
    9. Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 30(14):1715-24, 2012.
    10. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 34(6):611-35, 2016.
    11. Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol. 2011 Mar 20;29(9):1101-9, 2011.
    12. Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer survivors. J Clin Oncol. 31(28):3540-8, 2013.
    13. Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol. 25(28):4387-95, 2007.
    14. Smith AW, Alfano CM, Reeve BB, et al. Race/ethnicity, physical activity, and quality of life in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 18(2):656-63, 2009.
    15. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 8:CD007566, 2012.
    16. Pennington KP, McTiernan A. The role of physical activity in breast and gynecologic cancer survivorship. Gynecol Oncol. 149(1):198-204, 2018.
    17. Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat. 123(2):507-24, 2010.
    18. Leung J, Smith MD, McLaughlin D. Inequalities in long term health-related quality of life between partnered and not partnered breast cancer survivors through the mediation effect of social support. Psychooncology. 25(10):1222-1228, 2016.
    19. Syrowatka A, Motulsky A, Kurteva S, et al. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat. 165(2):229-245, 2017.
    20. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. J Clin Psychol. 57(4):501-19, 2001.
    21. Perkins EA, Small BJ, Balducci L, Extermann M, Robb C, Haley WE. Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol Hematol. 62(1):74-83, 2007.
    22. McLaughlin SA. Chapter 40: Lymphedema, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    23. National Cancer Institute. Lymphedema –health professional version: overview. https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq, 2015.
    24. Dominick SA, Madlensky L, Natarajan L, Pierce JP. Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv. 7(1):115-23, 2013.
    25. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14(6):500-15, 2013.
    26. Asdourian MS, Swaroop MN, Sayegh HE, et al. Association between precautionary behaviors and breast cancer-related lymphedema in patients undergoing bilateral surgery. J Clin Oncol. 35(35):3934-3941, 2017.
    27. Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 24(10):2972-2980, 2017.
    28. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Survivorship. V.1.2018. http://www.nccn.org, 2018.
    29. Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. Plast Reconstr Surg. 129(5):789e-95e, 2012.
    30. McLaughlin SA, Bagaria S, Gibson T, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 216(3):380-9, 2013.
    31. Miller CL, Colwell AS, Horick N, et al. Immediate implant reconstruction is associated with a reduced risk of lymphedema compared to mastectomy alone: a prospective cohort study. Ann Surg. 263(2):399-405, 2016.
    32. Menezes MM, Bello MA, Millen E, et al. Breast reconstruction and risk of lymphedema after mastectomy: A prospective cohort study with 10 years of follow-up. J Plast Reconstr Aesthet Surg. 69(9):1218-26, 2016.
    33. Siotos C, Sebai ME, Wan EL, et al. Breast reconstruction and risk of arm lymphedema development: A meta-analysis. J Plast Reconstr Aesthet Surg. 71(6):807-818, 2018.
    34. De Gournay E, Guyomard A, Coutant C, et al. Impact of sentinel node biopsy on long-term quality of life in breast cancer patients. Br J Cancer. 109(11):2783-91, 2013.
    35. Wetzig N, Gill PG, Espinoza D, et al. Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 24(4):1064-1070, 2017.
    36. Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol. 30(30):3726-33, 2012.
    37. National Cancer Institute. Lymphedema –health professional version: management. https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq#section/_40, 2015.
    38. Shah C, Vicini FA. Breast cancer-related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys. 81(4):907-14, 2011.
    39. Hayes SC, Johansson K, Stout NL, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 118(8 Suppl):2237-49, 2012.
    40. Gratzon A, Schultz J, Secrest K, Lee K, Feiner J, Klein RD. Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy. Ann Surg Oncol. 24(6):1475-1481, 2017.
    41. Gratzon A, Schultz J, Secrest K, Lee K, Feiner J, Klein RD. Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy. Ann Surg Oncol. 24(6):1475-1481, 2017.
    42. Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 132(5):1305-14, 2013.
    43. Silva AK, Chang DW. Vascularized lymph node transfer and lymphovenous bypass: Novel treatment strategies for symptomatic lymphedema. J Surg Oncol. 113(8):932-9, 2016.
    44. Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 304(24):2699-705, 2010.
    45. McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev. (6):CD005211, 2010.
    46. Kwan ML, Cohn JC, Armer JM, Stewart BR, Cormier JN. Exercise in patients with lymphedema: a systematic review of the contemporary literature. J Cancer Surviv. 5(4):320-36, 2011.
    47. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 361(7):664-73, 2009.
    48. Speck RM, Gross CR, Hormes JM, et al. Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat. 121(2):421-30, 2010.
    49. Baumann FT, Reike A, Reimer V, et al. Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 170(1):1-13, 2018.
    50. Mehrara B. Breast cancer-associated lymphedema, in Up-to-Date (Hayes DF, Nekhlyudov L, Bruera E, Ganz PA, Collins KA, Vora SR, editors.). Up-to-Date, 2018.
    51. Holmberg L, Iverson OE, Rudenstam CM, et al., for the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.J Natl Cancer Inst. 100(7):475-82, 2008.
    52. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 49(1):52-9, 2013.
    53. Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr. for the Study Groups on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol. 101(2):346-52, 2003.
    54. Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat.135:603–9, 2012.
    55. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 127(3):e93-6, 2016.
    56. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 25(1):11-20, 2018.
    57. Mazzarello S, Hutton B, Ibrahim MF, et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat. 152(1):1-8, 2015.
    58. Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 3(3):313-319, 2017.
    59. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 33(30):3394-400, 2015.
    60. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 27(17):2831-7, 2009.
    61. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 28(20):3278-83, 2010.
    62. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 305(3):267-74, 2011.
    63. Pinkerton JV, Constantine G, Hwang E, et al. for the Study 3353 Investigators. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 20(1):28-37, 2013.
    64. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 29(1):204-13, 2014.
    65. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 174(7):1058-66, 2014.
    66. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 340:c693, 2010.
    67. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 366(9488):818-24, 2005.
    68. Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric. 12(4):310-8, 2009.
    69. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 28(35):5147-52, 2010.
    70. Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M for the Breeze 3 Investigators. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause. 21(6):567-73, 2014.
    71. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 26(10):1650-6, 2008.
    72. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 16: 495-500, 1998.
    73. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 18(5): 1068-74, 2000.
    74. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 20(6):1449-55, 2002.
    75. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 24(18):2836-41, 2006.
    76. Bolaños R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 17(3):660-6, 2010.
    77. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 9:CD007244, 2012.
    78. Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA. 315(23):2554-63, 2016.
    79. Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev. 3:CD009023, 2016.
    80. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 26(10):1578-86, 2004.
    81. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 355(22):2338-47, 2006.
    82. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 19(10):1669-80, 2008.
    83. Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause. 16(2):357-66, 2009.
    84. Joffe H, Partridge A, Giobbie-Hurder A, et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 17(5):908-16, 2010.
    85. Pruthi S, Qin R, Terstreip SA, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 19(1):48-53, 2012.
    86. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position. Menopause. 20(9):888-902, 2013.
    87. North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 22(11):1155-72, 2015.
    88. Deng G, Vickers A, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol. 25(35):5584-90, 2007.
    89. Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev. 7:CD007410, 2013.
    90. Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause. 22(2):234-44, 2015.
    91. Garcia MK, Graham-Getty L, Haddad R, et al. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 121(22):3948-58, 2015.
    92. Ee C, Xue C, Chondros P, et al. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med. 164(3):146-54, 2016.
    93. Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 30(33):4124-33, 2012.
    94. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 13(3):309-18, 2012.
    95. Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 19(8):2357-2363, 2001.
    96. Hummel SB, van Lankveld JJDM, Oldenburg HSA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol. 35(12):1328-1340, 2017.
    97. The North American Menopause Society. Breast cancer survivors & hot flash treatments. https://www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/breast-cancer-survivors-hot-flash-treatments, 2018.
    98. Sood R, Shuster L, Smith R, Vincent A, Jatoi A. Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians. J Am Board Fam Med. 24(2):202-10, 2011.
    99. U.S. Food and Drug Administration (FDA). Menopause. https://www.fda.gov/forconsumers/byaudience/forwomen/ucm117978.htm, 2018.
    100. Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer. 98(6): 1131-40, 2003.
    101. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 47(4):545-9, 2008.
    102. Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 47(1):74-83, 2011.
    103. Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 160(2):347-360, 2016.
    104. Iqbal J, Amir E, Rochon PA, Giannakeas V, Sun P, Narod SA. Association of the timing of pregnancy with survival in women with breast cancer. JAMA Oncol. 2017 May 1;3(5):659-665, 2017.
    105. Moran MS, Colasanto JM, Haffty BG, Wilson LD, Lund MW, Higgins SA. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J. 11(5):399-403, 2005.
    106. de Bree E, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiftsis DD. Pregnancy after breast cancer. A comprehensive review. J Surg Oncol. 101(6):534-42, 2010.
    107. Lengacher CA, Reich RR, Paterson CL, et al. Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 34(24):2827-34, 2016.
    108. Carlson RW. Chapter 67: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    109. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 34(9):927-35, 2016.
    110. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 56(4):1038-45, 2003.
    111. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat. 105(2):195-207, 2007.
    112. Ricceri F, Fasanelli F, Giraudo MT, et al. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 137(4):940-8, 2015.
    113. Lee JM, Buist DS, Houssami N, et al. Five-year risk of interval-invasive second breast cancer. J Natl Cancer Inst. 107(7), 2015.
    114. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA. 312(9):902-14, 2014.
    115. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 22(12):2328-35, 2004.
    116. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 27(35):5887-92, 2009.
    117. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 28(14):2404-10, 2010.
    118. Domchek SM, Peshkin BN, Schwartz MD, Isaacs C. Chapter 17: Genetic Testing and Management of Patients with Hereditary Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    119. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 104(9):1384-92, 2011.
    120. van den Broek AJ, van 't Veer LJ, Hooning MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clin Oncol. 34(5):409-18, 2016.
    121. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 317(23):2402-2416, 2017.
    122. National Cancer Institute. Genetics of breast and gynecologic cancers-for health professionals (PDQ). http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq#section/_88, 2018.
    123. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 28(3):509-18, 2010.
    124. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 136(2):495-502, 2012.
    125. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 108(7):1515-24, 2013.
    126. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 34(21):2452-9, 2016.
    127. Kroenke CH, Kwan ML, Neugut AI, et al. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast Cancer Res Treat. 139(2):515-27, 2013.
    128. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Distress management. V.2.2018. http://www.nccn.org, 2018.
    129. Huang HP, He M, Wang HY, Zhou M. A meta-analysis of the benefits of mindfulness-based stress reduction (MBSR) on psychological function among breast cancer (BC) survivors. Breast Cancer. 23(4):568-76, 2016.
    130. Lyman GH, Greenlee H, Bohlke K, e al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 1;36(25):2647-2655, 2018.
    131. Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 17(3):337-46, 2015.
    132. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: the SWORD study, a randomized controlled trial. J Clin Oncol. 35(19):2173-2183, 2017.
    133. Abrahams HJG, Gielissen MFM, Donders RRT, et al. The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial. Cancer. 123(19):3825-3834, 2017.
    134. Compen F, Bisseling E, Schellekens M, et al. Face-to-face and internet-based mindfulness-based cognitive therapy compared with treatment as usual in reducing psychological distress in patients with cancer: a multicenter randomized controlled trial. J Clin Oncol. 36(23):2413-2421, 2018.
    135. Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol. 32(6):557-63, 2014.
    136. Duijts SF, Faber MM, Oldenburg HS, van Beurden M, Aaronson NK. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis. Psychooncology. 20(2):115-26, 2011.
    137. Buffart LM, van Uffelen JG, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 12:559, 2012.
    138. Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 15:77, 2015.
    139. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 344:e70, 2012.
    140. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 11:CD006145, 2012.
    141. Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 118(15):3766-75, 2012.
    142. Hayes SC, Rye S, Disipio T, et al. Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Res Treat. 137(1):175-86, 2013.
    143. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 1:CD010802, 2017.
    144. Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY. The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer. Cancer. 124(4):797-806, 2018.
    145. Kushi LH, Doyle C, McCullough M, et al. for the American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 62(1):30-67, 2012.
    146. Hill EK, Sandbo S, Abramsohn E, et al. Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 117(12):2643-51, 2011.
    147. Syrjala KL, Yi JC. Overview of psychosocial issues in the adult cancer survivors, in Up-to-Date (Ganz PA, Vora SR, eds.). Up-to-Date, 2016.
    148. Falk SJ. Overview of sexual dysfunction in female cancer survivors, in Up-to-Date (Ganz PA, Vora SR, eds.). Up-to-Date, 2018.
    149. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 26(5):753-8, 2008.
    150. Champion VL, Wagner LI, Monahan PO, et al. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer. 120(15):2237-46, 2014.
    151. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat. 144(1):185-92, 2014.
    152. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment—breast and ovarian, Version 2.2019. http://www.nccn.org, 2018.
    153. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358: 1389-99, 2001.
    154. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 62(4):243-74, 2012.
    155. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 23(7):1370-8, 2005.
    156. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 111(2):329-42, 2008.
    157. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 123(3):627-35, 2010.
    158. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 29(1):25-31, 2011.
    159. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer. 15:865, 2015.
    160. Cecchini R, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev. 25(1):51-9, 2016.
    161. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 18(5):1403-9, 2009.
    162. Imkampe AK, Bates T. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis. Breast J. 16(2):156-61, 2010.
    163. Bradshaw PT, Ibrahim JG, Stevens J, et al. Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology. 23(2):320-327, 2012.
    164. Centers for Disease Control and Prevention. The health effects of overweight and obesity. https://www.cdc.gov/healthyweight/effects/index.html, 2015.
    165. American Cancer Society. Does body weight affect cancer risk? https://www.cancer.org/cancer/cancer-causes/diet-physical-activity/body-weight-and-cancer-risk/effects.html, 2018.
    166. McCullough ML, Patel AV, Kushi LH, et al. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease and all-cause mortality. Cancer Epidemiol Biomarkers Prev. 20(6):1089-97, 2011.
    167. Rock CL, Natarajan L, Pu M, et al. for the Women's Healthy Eating and Living Study Group. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women's Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev. 18(2):486-94, 2009.
    168. Beasley JM, Newcomb PA, Trentham-Dietz A, et al. Post-diagnosis dietary factors and survival after invasive breast cancer. Breast Cancer Res Treat. 128(1):229-36, 2011.
    169. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1029 –35, 1994.
    170. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer. 127(1):172-84, 2010.
    171. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP.. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 159(12):824-34, 2013.
    172. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 98(24):1767-76, 2006.
    173. Chlebowski RT, Aragaki AK, Anderson GL, et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the Women's Health Initiative randomized clinical trial. JAMA Oncol. 2018 May 24 [Epub ahead of print].
    174. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 298(3):289-98, 2007.
    175. Holmes MD, Chen WY, Hankinson SE, Willett WC. Physical activity’s impact on the association of fat and fiber intake with survival after breast cancer. Am J Epidemiol. 170(10):1250-56, 2009.
    176. Kroenke CH, Kwan ML, Sweeney C, Castillo A, Caan BJ. High- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis. J Natl Cancer Inst. 105(9):616-23, 2013.
    177. Brennan SF, Woodside JV, Lunny PM, Cardwell CR, Cantwell MM. Dietary fat and breast cancer mortality: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 57(10):1999-2008, 2017.
    178. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA. 302(22):2437-43, 2009.
    179. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 96(1):123-32, 2012.
    180. Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 14(4):2407-12, 2013.
    181. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 98(1):9-14, 2008.
    182. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 125(2): p. 315-23, 2011.
    183. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 57(5):260-77, 2007.
    184. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 12:CD001395, 2013.
    185. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol. 28(29):4410-6, 2010.
    186. Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 19(3):681-8, 2010.
    187. Kwan ML, Chen WY, Flatt SW, et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 22(1):32-41, 2013.
    188. Newcomb PA, Kampman E, Trentham-Dietz A, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 31(16):1939-46, 2013.
    189. Ali AM, Schmidt MK, Bolla M, et al. Alcohol consumption and survival after a breast cancer diagnosis: A literature-based meta-analysis and collaborative analysis of data for 29,239 cases. Cancer Epidemiol Biomarkers Prev. 23(6):934-45, 2014.
    190. Lowry SJ, Kapphahn K, Chlebowski R, Li CI. Alcohol use and breast cancer survival among participants in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 25(8):1268-73, 2016.
    191. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. 332(19):1245-50, 1995.
    192. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 302(4):401-11, 2009.
    193. Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project. Breast Cancer Res Treat. 131(2):637-43, 2012.
    194. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 293(20):2479-86, 2005.
    195. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(2):379-86, 2008.
    196. Chen X, Lu W, Zheng W, et al. Exercise after diagnosis of breast cancer in association with survival. Cancer Prev Res (Phila). 4(9):1409-18, 2011.
    197. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 25(7):1293-311, 2014.
    198. Nechuta S, Chen WY, Cai H, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer. 138(9):2088-97, 2016.
    199. Maliniak ML, Patel AV, McCullough ML, et al. Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res Treat. 167(1):133-145, 2018.
    200. Jones LW, Habel LA, Weltzien E, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 34(23):2743-9, 2016.
    201. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 25(13):1713-21, 2007.
    202. Mutrie N, Campbell AM, Whyte F, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ. 334(7592):517, 2007.
    203. Alfano CM, Smith AW, Irwin ML, et al. Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv. 1(2):116-28, 2007.
    204. Penttinen HM, Saarto T, Kellokumpu-Lehtinen P, et al. Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments. Psychooncology. 20(11):1211-20, 2011.
    205. Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. J Natl Cancer Inst. 106(1):djt359, 2014.
    206. National Cancer Institute. Harms of cigarette smoking and health benefits of quitting. http://www.cancer.gov/cancertopics/factsheet/Tobacco/cessation, 2014.
    207. Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 24(3):345-53, 2006.
    208. Tiedtke C, de Rijk A, Dierckx de Casterlé B, Christiaens MR, Donceel P. Experiences and concerns about 'returning to work' for women breast cancer survivors: a literature review. Psychooncology. 19(7):677-83, 2010.
    209. Wang L, Hong BY, Kennedy SA, et al. Predictors of unemployment after breast cancer surgery: a systematic review and meta-analysis of observational studies. J Clin Oncol. 36(18):1868-1879, 2018.
    210. Blinder VS, Patil S, Thind A, et al. Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer. 118(6):1664-74, 2012.
    211. Lundh MH, Lampic C, Nordin K, et al. Changes in health-related quality of life by occupational status among women diagnosed with breast cancer-a population-based cohort study. Psychooncology. 22(10):2321-31, 2013.  
    212. Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause. 2018 Dec 17. [Epub ahead of print].
    213. Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 379(20):1937-1944, 2018.
    214. Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer. 125(6):854-862, 2019.
    215. Kilgore LJ, Korentager SS, Hangge AN, et al. Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient directed self-interventions. Ann Surg Oncol. 25(10):2948-2952, 2018.
    216. Siotos C, Hassanein AH, Bello RJ, et al. Delayed breast reconstruction on patients with upper extremity lymphedema: a systematic review of the literature and pooled analysis. Ann Plast Surg. 81(6):730-735, 2018.
    217. Ammitzbøll G, Johansen C, Lanng C, et al. Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial. Cancer. 2019 Jan 11. [Epub ahead of print].

    Updated 04/22/19


    Survivorship Topics




Tools & Resources


Related Video



1-877 GO KOMEN